Europe Gastrointestinal Drugs Market to Grow at a CAGR of 4.4% to reach US$ 17,810.81 Million from 2020 to 2027

Europe Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, and Others); Route of Administration (Oral, and Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, and Others); and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country

Publication Month: Nov 2020 | Report Code: TIPRE00016280 | No. of Pages: 155 | Category: Pharmaceuticals | Status: Published
Covid

The Europe gastrointestinal drugs market is expected to reach US$ 17,810.81 million by 2027 from US$ 12,721.85 million in 2019; it is estimated to grow at a CAGR of 4.4% from 2020 to 2027.

Rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the key factors driving the growth of gastrointestinal drugs. However, side effects associated with the drugs is the major factor hindering the market growth in Europe.

 

Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhoea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.

 

The European Medicines Agency approved the first biosimilar therapies in 2006. Europe has the largest number of approved biosimilar medicines owing to high biologic costs and demand for cheaper medicines. For example, several adalimumab biosimilars were launched in 2019 in Europe. Europe has witnessed a smooth transition toward the use of biosimilars owing to its well-established regulatory framework. However, due to lack of regulation, there are very few approved biosimilars in gastroenterology with more in the pipeline. In January 2016, 22 biosimilars have been approved by the European Medicines Agency. The first biosimilars for inflammatory bowel disease (IBD) in the European Union were registered in 2013, and the first use of biosimilars of infliximab (reference product Remicade, Janssen) began around the spring and summer of 2014. The approval of a biosimilar in GI disorders is expected to increase in the coming years.

For instance, In July 2020, Celltrion Healthcare received marketing authorization approval the European Commission (EC) for Remsima (infliximab, CT-P13). It is a subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis.  Moreover, despite regulatory hurdles for the biosimilar market, it is still projected to grow at a rapid rate due to the need for cheaper alternatives to biologics. High costs associated with the manufacturing of biologic medicines have made biosimilar an attractive option for drug manufacturers, providing a platform for further growth.

 

The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Short-term impacts of COVID-19 pandemic includes demand changes, revision in regulatory process, changes in research and development process and the shift towards tele-communication and tele-medicine. But the growing awareness about gastrointestinal products available in market in Europe during is likely to demand for constipation drug products and supply in COVID-19 Pandemic, hence it can boost the growth of the gastrointestinal drugs market.

                                                                            

Rest of Europe Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)

Rest of Europe Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)

Get more information on this report :

 

EUROPE GASTROINTESTINAL DRUGS MARKET SEGMENTATION

 

By Drug Class

  • Acid Neutralizers
  • Antidiarrheal and Laxatives
  • Anti-Inflammatory Drugs
  • Antiemetic and Antinauseants
  • Biologics
  • Others

 

By Route of Administration

  • Oral
  • Parenteral

 

By Application

  • Inflammatory Ulcerative Colitis
  • Crohn's Disease
  • Irritable Bowel Syndrome
  • Gastroenteritis
  • Celiac Disease
  • Others

 

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

 

By Country

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

 

Company Profiles

  • Johnson and Johnson Services, Inc.
  • Sanofi
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Bayer AG

1.          Introduction

1.1        Scope of the Study

1.2        The Insight Partners Research Report Guidance

1.3        Market Segmentation

1.3.1        Europe Gastrointestinal Drugs Market – By Drug Class

1.3.2        Europe Gastrointestinal Drugs Market – By Route of Administration

1.3.3        Europe Gastrointestinal Drugs Market – By Application

1.3.4        Europe Gastrointestinal drugs Market – By Distribution Channel

1.3.5        Europe Gastrointestinal drugs Market – By Country

2.          Europe Gastrointestinal Drugs Market – Key Takeaways

3.          Research Methodology

3.1        Coverage

3.2        Secondary Research

3.3        Primary Research

4.          Europe Gastrointestinal Drugs Market – Market Landscape

4.1        Overview

4.2        PEST Analysis

4.2.1        Gastrointestinal Drugs Market - Europe PEST Analysis

4.3        Expert Opinion

5.          Europe Gastrointestinal Drugs Market - Key Market Dynamics

5.1        Key Market Drivers

5.1.1        Rise in Prevalence of Gastrointestinal (GI) Diseases

5.1.2        Increase in Development of Biologics

5.2        Market Restraints

5.2.1        Side Effects Associated With The Drugs

5.3        Market Opportunities

5.3.1        Increasing Investment in Research Activities and Growing Pipeline of GI Candidates

5.4        Future Trends

5.4.1        Emergence of Biosimilars

5.5        Impact Analysis

6.          Gastrointestinal Drugs Market – Europe Analysis

6.1        Europe Gastrointestinal Drugs Market Revenue Forecasts and Analysis

7.          Europe Gastrointestinal Drugs Market Analysis And Forecasts To 2027 – By Drug Class

7.1        Overview

7.2        Europe Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)

7.2.1        Europe Gastrointestinal drugs Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)

7.3        Acid Neutralizers

7.3.1        Overview

7.3.2        Europe Acid Neutralizers Market Revenue and Forecast to 2027 (US$ Mn)

7.4        Antidiarrheal and Laxatives

7.4.1        Overview

7.4.2        Europe Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)

7.5        Anti-Inflammatory Drugs

7.5.1        Overview

7.5.2        Europe Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

7.6        Antiemetic and Antinauseants

7.6.1        Overview

7.6.2        Europe Antiemetic and Antinauseants Market Revenue and Forecast to 2027 (US$ Mn)

7.7        Biologics

7.7.1        Overview

7.7.2        Europe Biologics Market Revenue and Forecasts to 2027 (US$ Mn)

7.8        Others

7.8.1        Overview

7.8.2        Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)

8.          Europe Gastrointestinal Drugs Market Analysis – By Route of Administration

8.1        Overview

8.2        Europe Gastrointestinal Drugs Market, By Route of Administration 2019-2027 (%)

8.2.1        Europe Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

8.3        Oral

8.3.1        Overview

8.3.2        Europe Oral Market Revenue and Forecasts to 2027 (US$ Mn)

8.4        Parenteral

8.4.1        Overview

8.4.2        Europe Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)

9.          Europe Gastrointestinal Drugs Market Analysis – By Application

9.1        Overview

9.2        Europe Gastrointestinal Drugs Market, By Application 2019-2027 (%)

9.2.1        Europe Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Application (US$ Mn)

9.3        Inflammatory Ulcerative Colitis

9.3.1        Overview

9.3.2        Europe Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)

9.4        Crohn's Disease

9.4.1        Overview

9.4.2        Europe Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)

9.5        Irritable Bowel Syndrome

9.5.1        Overview

9.5.2        Europe Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)

9.6        Gastroenteritis

9.6.1        Overview

9.6.2        Europe Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)

9.7        Celiac Disease

9.7.1        Overview

9.7.2        Europe Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)

9.8        Others

9.8.1        Overview

9.8.2        Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)

10.       Europe Gastrointestinal Drugs Market Analysis – By Distribution Channel

10.1     Overview

10.2     Europe Gastrointestinal Drugs Market, By Distribution Channel 2019-2027 (%)

10.2.1     Europe Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)

10.3     Hospital Pharmacies

10.3.1     Overview

10.3.2     Europe Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

10.4     Retail Pharmacies

10.4.1     Overview

10.4.2     Europe Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

10.5     Online Pharmacies

10.5.1     Overview

10.5.2     Europe Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

11.       Gastrointestinal Drugs Market Revenue and Forecasts To 2027 – Geographical Analysis

11.1     Europe Gastrointestinal Drugs Market Revenue and Forecasts To 2027

11.1.1     Overview

11.1.2     Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (USD Million)

11.1.3     Europe: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.4     Europe: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.5     Europe: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.6     Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.7     Europe: Gastrointestinal Drugs Market, by Country, 2018 & 2027 (%)

11.1.8     Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.1       Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.2       Germany: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.8.3       Germany: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.8.4       Germany: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.8.5       Germany: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.9     UK: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.1       UK: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.2       UK: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.9.3       UK: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.9.4       UK: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.9.5       UK: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.10   France: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.1    France: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.2    France: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.10.3    France: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.10.4    France: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.10.5    France: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.11   Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.1    Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.2    Spain: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.11.3    Spain: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.11.4    Spain: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.11.5    Spain: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.12   Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.1    Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.2    Italy: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.12.3    Italy: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.12.4    Italy: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.12.5    Italy: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

11.1.13   Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.13.1    Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.13.2    Rest of Europe: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)

11.1.13.3    Rest of Europe: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)

11.1.13.4    Rest of Europe: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)

11.1.13.5    Rest of Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)

12.       Impact of COVID-19 Pandemic on Europe Gastrointestinal Drugs Market

12.1     Europe: Impact Assessment of COVID-19 Pandemic

13.       Company Profiles

13.1     Sanofi

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2     GlaxoSmithKline plc.

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3     AstraZeneca

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4     Bayer AG

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5     Johnson and Johnson Services, Inc.

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

14.       Appendix

14.1     Glossary of Terms

 


LIST OF TABLES

Table 1.            Europe Gastrointestinal drugs Market Revenue and Forecasts To 2027, By Drug Class (US$ Mn)

Table 2.            Europe Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

Table 3.            Europe Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Application (US$ Mn)

Table 4.            Europe Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)

Table 5.            Europe Gastrointestinal Drugs Market, by Drug Class– Revenue and Forecast to 2027 (USD Million)

Table 6.            Europe Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 7.            Europe Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 8.            Europe Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 9.            Germany Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 10.         Germany Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 11.         Germany Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 12.         Germany Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 13.         UK Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 14.         UK Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 15.         UK Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 16.         UK Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 17.         France Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 18.         France Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 19.         France Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 20.         France Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 21.         Spain Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 22.         Spain Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 23.         Spain Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 24.         Spain Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 25.         Italy Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 26.         Italy Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 27.         Italy Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 28.         Italy Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 29.         Rest of Europe Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 30.         Rest of Europe Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 31.         Rest of Europe Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 32.         Rest of Europe Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 33.         Glossary of Terms, Gastrointestinal Drugs Market

 


LIST OF FIGURES

Figure 1.          Gastrointestinal Drugs Market Segmentation

Figure 2.          Europe Gastrointestinal Drugs Market Overview

Figure 3.          Acid Neutralizers Segment Held Largest Share of Product in Gastrointestinal Drugs Market

Figure 4.          UK is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.          Europe Gastrointestinal Drugs Market - Leading Country Markets (US$ Mn)

Figure 6.          Gastrointestinal Drugs Market - Europe PEST Analysis

Figure 7.          Gastrointestinal Drugs Market Impact Analysis of Drivers and Restraint

Figure 8.          Europe Gastrointestinal Drugs market – Revenue Forecasts and Analysis – 2019- 2027

Figure 9.          Europe Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)

Figure 10.        Europe Acid Neutralizers Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11.        Europe Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        Europe Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13.        Europe Antiemetic and Antinauseants Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        Europe Biologics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15.        Europe Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        Europe Gastrointestinal Drugs Market, by Route of Administration 2019 & 2027 (%)

Figure 17.        Europe Oral Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18.        Europe Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19.        Europe Gastrointestinal Drugs Market, by Application 2019 & 2027 (%)

Figure 20.        Europe Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21.        Europe Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 22.        Europe Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23.        Europe Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 24.        Europe Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25.        Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 26.        Europe Gastrointestinal Drugs Market, by Distribution Channel 2019 & 2027 (%)

Figure 27.        Europe Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 28.        Europe Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 29.        Europe Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 30.        Europe: Gastrointestinal Drugs Market, by Key Country – Revenue (2019) (USD Million)

Figure 31.        Europe Gastrointestinal Drugs Market Revenue and Forecast to 2027 (USD Million)

Figure 32.        Europe: Gastrointestinal Drugs Market, by Country, 2018 & 2027 (%)

Figure 33.        Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 34.        UK: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 35.        France: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 36.        Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 37.        Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 38.        Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 39.        Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in European Countries

The List of Companies - Europe Gastrointestinal Drugs Market

  1. Sanofi
  2. GlaxoSmithKline plc
  3. Johnson and Johnson Services, Inc.
  4. AstraZeneca
  5. Bayer AG
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe gastrointestinal drugs market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Europe gastrointestinal drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution. 
TIPRE00016280
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing